A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors

Protocol No
TOLERO-TP-1287-101
Principal Investigator
Ben George
Phase
I
Summary
This study is testing an “investigational” compound called TP-1287. “Investigational” means that the Food and Drug Administration (FDA) has not yet approved this drug as a prescription medicine; it is only available through research studies like this. TP-1287 is a NEW, investigational product being developed by Tolero Pharmaceuticals as a therapy for advanced metastatic or progressive solid tumors. TP-1287 has been tested extensively in animals and in the laboratory, but this will be the first time that TP 1287 will be given to humans in a clinical trial. TP-1287 is a CDK9 inhibitor that blocks certain cancer cell growth functions which may lead to cancer cell death.
Description
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: